February 13th 2025
Barbieri et al evaluated product use, benzoyl peroxide concentration, days until expiration, and more.
FDA Accepts Accord BioPharma's BLA for Proposed Ustekinumab Biosimilar DMB-3115
January 4th 2024The BLA submission for DMB-3115 is rooted in phase III multi-regional clinical trials focusing on plaque psoriasis patients. The results demonstrated a high similarity between DMB-3115 and ustekinumab in terms of quality, safety, and efficacy.
FDA Approves Historic Roflumilast Foam 0.3% For Seborrheic Dermatitis
December 15th 2023Roflumilast foam 0.3% is the first FDA-approved drug for seborrheic dermatitis with a new mechanism of action in over 2 decades. Christopher Bunick, MD, PhD; Shawn Kwatra, MD; and Peter Lio, MD, share expert insights.